KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Common Equity (2016 - 2025)

Historic Common Equity for Pacific Biosciences Of California (PACB) over the last 17 years, with Q3 2025 value amounting to $36.1 million.

  • Pacific Biosciences Of California's Common Equity fell 9203.53% to $36.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.1 million, marking a year-over-year decrease of 9203.53%. This contributed to the annual value of $506.6 million for FY2024, which is 2776.4% down from last year.
  • Latest data reveals that Pacific Biosciences Of California reported Common Equity of $36.1 million as of Q3 2025, which was down 9203.53% from $61.5 million recorded in Q2 2025.
  • Pacific Biosciences Of California's Common Equity's 5-year high stood at $840.8 million during Q3 2021, with a 5-year trough of $36.1 million in Q3 2025.
  • Moreover, its 5-year median value for Common Equity was $626.6 million (2022), whereas its average is $519.3 million.
  • Per our database at Business Quant, Pacific Biosciences Of California's Common Equity surged by 54929.19% in 2021 and then crashed by 9203.53% in 2025.
  • Over the past 5 years, Pacific Biosciences Of California's Common Equity (Quarter) stood at $791.0 million in 2021, then dropped by 28.84% to $562.9 million in 2022, then grew by 24.59% to $701.3 million in 2023, then decreased by 27.76% to $506.6 million in 2024, then crashed by 92.88% to $36.1 million in 2025.
  • Its Common Equity stands at $36.1 million for Q3 2025, versus $61.5 million for Q2 2025 and $91.6 million for Q1 2025.